Vasopharm grabs almost $22 mln
Germany-based Vasopharm, a biopharmaceutical company focused on treating cerebrovascular diseases, has secured 20 million euros (almost $22 million) in funding. Entrepreneurs Fund, Heidelberg Capital Private Equity and Fort Rock Capital led the round. Other investors were Bayern Kapital and funds advised by Hanseatic Asset Management LBG. In addition to the funding, Dr Mario Alberto Accardi, a venture partner at Fort Rock Capital, has been added to Vasopharm's board of directors.
21 January 2016•4 mins read
